CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	225.67	389.48	211.89	923.03	1,169	943.77
Short-Term Investments	1,710	1,304	1,603	1,456	521.71	-
Cash & Short-Term Investments	1,936	1,694	1,815	2,379	1,690	943.77
Cash Growth	11.26%	-6.70%	-23.70%	40.75%	79.10%	106.67%
Accounts Receivable	-	200	-	0.31	0.14	32.7
Other Receivables	-	6.5	11.2	8.4	10.7	4.1
Receivables	-	206.5	11.2	8.71	10.84	36.8
Prepaid Expenses	8.25	7.89	26.01	29.68	15.44	6.98
Restricted Cash	-	-	0.5	-	-	-
Total Current Assets	1,944	1,908	1,853	2,418	1,717	987.55
Property, Plant & Equipment	284.83	305.94	320.56	312.04	93.03	72.83
Long-Term Investments	-	1.97	53.13	-	-	-
Other Intangible Assets	-	0.02	0.07	0.13	0.18	0.24
Other Long-Term Assets	27.41	13.57	16.28	22.2	18.14	6.14
Total Assets	2,256	2,230	2,243	2,752	1,828	1,067
Accounts Payable	15.58	38.15	27.43	14.82	9.09	5.94
Accrued Expenses	35.55	40.67	61.33	77.77	54.32	27.46
Current Portion of Leases	16.88	15.63	15.84	12.16	11.36	8.49
Current Income Taxes Payable	0.84	0.44	0.14	0.72	10.47	0.58
Current Unearned Revenue	4.48	4.11	-	1.01	2.34	0.96
Other Current Liabilities	16.47	9.81	16.38	13.4	6.67	13.67
Total Current Liabilities	89.81	108.79	121.11	119.88	94.26	57.11
Long-Term Leases	210.66	223.01	228.18	212.87	50.07	44.05
Long-Term Unearned Revenue	12.32	14.01	12.32	12.32	11.78	11.78
Other Long-Term Liabilities	3.68	0.96	5.97	7.34	7.63	14.4
Total Liabilities	316.47	346.77	367.58	352.42	163.73	127.33
Common Stock	2.68	2.5	2.44	2.39	2.28	1.85
Additional Paid-In Capital	3,255	2,878	2,735	2,598	2,236	1,162
Retained Earnings	-1,329	-999.7	-846.09	-195.92	-573.58	-224.71
Treasury Stock	-0.06	-0.06	-0.06	-0.06	-0.06	-0.06
Comprehensive Income & Other	10.57	1.91	-15.65	-5.07	-0.08	0.01
Total Common Equity	1,940	1,883	1,875	2,399	1,664	939.43
Shareholders' Equity	1,940	1,883	1,875	2,399	1,664	939.43
Total Liabilities & Equity	2,256	2,230	2,243	2,752	1,828	1,067
Total Debt	227.55	238.63	244.02	225.03	61.43	52.54
Net Cash (Debt)	1,708	1,457	1,624	2,154	1,629	891.23
Net Cash Growth	14.01%	-10.30%	-24.59%	32.24%	82.77%	95.17%
Net Cash Per Share	20.60	18.39	20.89	26.79	24.70	15.65
Filing Date Shares Outstanding	85.35	80.28	78.65	77.07	75.43	60.85
Total Common Shares Outstanding	85.34	80.04	78.51	76.99	73.91	60.78
Working Capital	1,854	1,799	1,732	2,298	1,622	930.44
Book Value Per Share	22.73	23.52	23.89	31.17	22.52	15.46
Tangible Book Value	1,940	1,883	1,875	2,399	1,664	939.19
Tangible Book Value Per Share	22.73	23.52	23.89	31.16	22.51	15.45
Machinery	54.67	53.26	49.62	36.25	29.5	20.58
Construction In Progress	8.4	8.86	6.16	52.4	8.37	1.39
Leasehold Improvements	143.26	143.26	141.68	86.74	25.47	21.4

Source: S&P Capital IQ. Standard template. Financial Sources.